One of the lead candidates in Sanofi natural killer (NK) cell engager alliance with Innate Pharma has shown encouraging and durable efficacy in various haematological cancers, according to a phase 1/2 study presented at the EHA congress.SAR443579 (also known as IPH6101) is a trifunctional NKp46/CD16-based anti-CD123 NK cell engager – described as a first-in-class therapy – that has now advanced into a phase 2 programme. It was the first candidate taken forward by Sanofi after it signed its first partnership with Innate in 2016.
